SCHEMBL2472469

SCHEMBL2472469

CCN(OC)S(=O)(=O)C(NC(=O)c1ccccc1OC)C1(Cc2ccccc2)CCNCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.40
TP53 P04637 2/20 0.40
GLA P06280 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CHRM3 P20309 1/20 0.39
ITGB1 P05556 2/20 0.38
ITGA4 P13612 2/20 0.38
ITGB7 P26010 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SLC6A9 P48067 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
LMNA P02545 1/20 0.36
CTSD P07339 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KCNA3 P22001 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471065 0.89 HPGD (0.42) HPGDTP53GLAALDH1A1CHRM3
SCHEMBL2471728 0.88 ALDH1A1 (0.42) HPGDTP53GLAALDH1A1ITGB1
SCHEMBL2497213 0.84 MEN1 (0.42) HPGDALDH1A1ITGB1ITGA4ITGB7
SCHEMBL2701752 0.80 ALDH1A1 (0.41) HPGDALDH1A1ITGB1ITGA4ITGB7
SCHEMBL2470897 0.79 HPGD (0.43) HPGDTP53GLAALDH1A1CHRM3
SCHEMBL2469459 0.78 SLC6A9 (0.44) HPGDALDH1A1CHRM3ITGB1ITGA4
SCHEMBL2468186 0.77 ALDH1A1 (0.42) HPGDTP53GLAALDH1A1ITGB1
SCHEMBL2473080 0.77 ALDH1A1 (0.42) HPGDTP53GLAALDH1A1ITGB1
SCHEMBL2472012 0.77 ALDH1A1 (0.42) HPGDALDH1A1ITGB1ITGA4ITGB7
SCHEMBL2467873 0.75 L3MBTL1 (0.45) HPGDTP53GLAALDH1A1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 HPGD 1527/4885TP53 4255/4885GLA 3436/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 HPGD 1527/4885TP53 4255/4885GLA 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.